Medpace Investors Urged to Seek Lead Role in Securities Suit Before June 8 Deadline
Plaintiffs say Medpace overstated expected bookings, then disclosed a lower fourth‑quarter figure that sent shares down 15.9%.
Overview
- Pomerantz and Robbins, which issued investor notices on April 30, urged Medpace shareholders with losses to contact the firms before the June 8 lead‑plaintiff deadline.
- A filed class action seeks to represent investors who bought Medpace stock from April 22, 2025 through February 9, 2026.
- The complaint claims executives promoted a 1.15 book‑to‑bill outlook and described cancellations as "well‑behaved," creating expectations the company could not meet.
- Medpace reported a 1.04 book‑to‑bill ratio on February 9, 2026, and the stock fell 15.9% to close at $446.05 the next day.
- Book‑to‑bill compares new contract bookings to revenue in a period, so a drop can signal slower future work for contract research firms and can hit valuations.